Martek Announces Third Quarter 2009 Financi...(and $11.8 million and diluted earnings p...),Health

For the full fiscal year 2009, Martek expects total revenues to be between $345 million and $350 million. Net income for the full fiscal year 2009 is projected to be between $40.0 million and $41.4 million, and diluted earnings per share are projected to be between $1.20 and $1.24, a pre-tax earnings increase of between 10% and 15% over fiscal 2008.

Investor Conference Call Webcast

Martek will host a conference call and Webcast for investors to review its third quarter results and fiscal 2009 outlook at 4:45 p.m. Eastern Time on Wednesday, September 2, 2009. Access to the live audio Webcast is available through Martek's website at http://investors.martek.com. The webcast will be available for replay through the close of business on October 2, 2009.

General

Sections of this release contain forward-looking statements concerning, among other things: (1) Martek's expectations regarding future revenue growth in and customer demand from the infant formula, pregnancy and nursing, nutritional supplements, animal feeds and food and beverage markets; (2) its expectations regarding revenue, gross margin, operating expenses and income for the fourth quarter of and full fiscal year 2009; (3) its expectations and beliefs regarding the impact of customer de-stocking on revenues in the fourth quarter of fiscal 2009; and (4) its expectations regarding launches by customers of products containing Martek's life'sDHA(TM) and Martek's contract manufacturing business. Furthermore, Martek's operating results are subject to quarter-to-quarter fluctuations, some of which may be significant. The forward-looking statements noted above are based upon numerous assumptions which Martek canno
'/>"/>